Viatris (VTRS): Agrees to buy Pacira BioSciences for $1.65 billion in cash
Viatris agreed to buy Pacira for $36.50 a share in cash, about $1.65B, adding non-opioid pain drugs Exparel and Zilretta. Pacira jumped roughly 44%; Viatris slipped nearly 2%. Close is targeted by end-2026.
Why it matters Viatris is pushing beyond generics into branded, patent-protected medicines, and the deal pairs with its fast-acting meloxicam candidate, which has an FDA decision due by Dec. 27.
What we verified Pacira's SEC filing and Reuters (via KSL) confirm $36.50 per share in cash, $1.65B, a tender offer with a second-step merger, and a close by end of 2026. The share moves are from Reuters morning-trading reports.
For information only. Not financial advice. See our disclaimer and editorial standards . Spotted an error? Tell us .
